Study S000460

Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With Type-2 Diabetes Mellitus (TRANSITION-T2D) A Prospective Randomized Controlled Trial

Included trial: extracted data ClinicalTrials.gov record Study Protocol and Statistical Analysis Plan (PDF)

Registration

Registration: NCT04538352
Acronym: TRANSITION-T2D
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: COMPLETED
Enrollment: 60
Start: 2021-01-18
Primary completion: 2023-03-31
Lead sponsor: The Cleveland Clinic
Conditions: Type 2 Diabetes
Interventions: DRUG:Semaglutide; DRUG:Insulin Degludec; DRUG:Insulin aspart
Results posted: TRUE
Individual participant data sharing: NO

Registered primary outcomes

Mean Change in HbA1C ≤ 7.5% [26 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0018231	De-intensification of basal-bolus therapy by replacing prandial insulin with once-weekly subcutaneous semaglutide in individuals with well-controlled type 2 diabetes: A single-centre, open-label randomised trial (TRANSITION-T2D). Rodriguez P, Diabetes, obesity & metabolism	2025	Randomized trial	PMID 39532398 DOI	registry reference RESULT:39532398